

Shingo Oda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6551417/publications.pdf>

Version: 2024-02-01

46
papers

946
citations

394421
19
h-index

477307
29
g-index

47
all docs

47
docs citations

47
times ranked

1358
citing authors

#	ARTICLE	IF	CITATIONS
1	A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metabolism and Pharmacokinetics, 2015, 30, 30-51.	2.2	186
2	Human UDP-Glucuronosyltransferase (UGT) 2B10 in Drug-N-Glucuronidation: Substrate Screening and Comparison with UGT1A3 and UGT1A4. Drug Metabolism and Disposition, 2013, 41, 1389-1397.	3.3	47
3	Toxicological potential of acyl glucuronides and its assessment. Drug Metabolism and Pharmacokinetics, 2017, 32, 2-11.	2.2	44
4	Interactions between human UDP-glucuronosyltransferase (UGT) 2B7 and UGT1A enzymes. Journal of Pharmaceutical Sciences, 2010, 99, 442-454.	3.3	37
5	Human UDP-Glucuronosyltransferase Isoforms Involved in Haloperidol Glucuronidation and Quantitative Estimation of Their Contribution. Drug Metabolism and Disposition, 2012, 40, 240-248.	3.3	35
6	A novel cell-based assay for the evaluation of immune- and inflammatory-related gene expression as biomarkers for the risk assessment of drug-induced liver injury. Toxicology Letters, 2016, 241, 60-70.	0.8	33
7	Identification of Specific MicroRNA Biomarkers in Early Stages of Hepatocellular Injury, Cholestasis, and Steatosis in Rats. Toxicological Sciences, 2018, 166, 228-239.	3.1	32
8	Progesterone Receptor Membrane Component 1 Modulates Human Cytochrome P450 Activities in an Isoform-Dependent Manner. Drug Metabolism and Disposition, 2011, 39, 2057-2065.	3.3	31
9	Epigenetic regulation of the tissue-specific expression of human UDP-glucuronosyltransferase (UGT) 1A10. Biochemical Pharmacology, 2014, 87, 660-667.	4.4	31
10	Preparation of a Specific Monoclonal Antibody against Human UDP-Glucuronosyltransferase (UGT) 1A9 and Evaluation of UGT1A9 Protein Levels in Human Tissues. Drug Metabolism and Disposition, 2012, 40, 1620-1627.	3.3	29
11	Epigenetic Regulation Is a Crucial Factor in the Repression of UGT1A1 Expression in the Human Kidney. Drug Metabolism and Disposition, 2013, 41, 1738-1743.	3.3	29
12	Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Toxicology Letters, 2014, 228, 13-24.	0.8	25
13	Toxicological role of an acyl glucuronide metabolite in diclofenac-induced acute liver injury in mice. Journal of Applied Toxicology, 2017, 37, 545-553.	2.8	25
14	Models of Idiosyncratic Drug-Induced Liver Injury. Annual Review of Pharmacology and Toxicology, 2021, 61, 247-268.	9.4	24
15	Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. Journal of Applied Toxicology, 2016, 36, 35-47.	2.8	22
16	Kupffer cell-mediated exacerbation of methimazole-induced acute liver injury in rats. Journal of Applied Toxicology, 2016, 36, 702-715.	2.8	21
17	Cell-based assay using glutathione-depleted HepaRG and HepG2 human liver cells for predicting drug-induced liver injury. Toxicology in Vitro, 2018, 48, 286-301.	2.4	21
18	Zomepirac Acyl Glucuronide Is Responsible for Zomepirac-Induced Acute Kidney Injury in Mice. Drug Metabolism and Disposition, 2016, 44, 888-896.	3.3	20

#	ARTICLE	IF	CITATIONS
19	miRNA in Rat Liver Sinusoidal Endothelial Cells and Hepatocytes and Application to Circulating Biomarkers that Discern Pathogenesis of Liver Injuries. <i>American Journal of Pathology</i> , 2018, 188, 916-928.	3.8	20
20	Targeted Screen for Human UDP-Glucuronosyltransferases Inhibitors and the Evaluation of Potential Drug-Drug Interactions with Zafirlukast. <i>Drug Metabolism and Disposition</i> , 2015, 43, 812-818.	3.3	18
21	Comprehensive analysis of serum microRNAs in hepatic sinusoidal obstruction syndrome (SOS) in rats: implication as early phase biomarkers for SOS. <i>Archives of Toxicology</i> , 2018, 92, 2947-2962.	4.2	16
22	A scrutiny of circulating microRNA biomarkers for drug-induced tubular and glomerular injury in rats. <i>Toxicology</i> , 2019, 415, 26-36.	4.2	15
23	An in vitro coculture system of human peripheral blood mononuclear cells with hepatocellular carcinoma-derived cells for predicting drug-induced liver injury. <i>Archives of Toxicology</i> , 2021, 95, 149-168.	4.2	14
24	Establishment of a drug-induced rhabdomyolysis mouse model by co-administration of ciprofloxacin and atorvastatin. <i>Toxicology Letters</i> , 2018, 291, 184-193.	0.8	13
25	Comparative hepatic transcriptome analyses revealed possible pathogenic mechanisms of fasiglifam (TAK-875)-induced acute liver injury in mice. <i>Chemico-Biological Interactions</i> , 2018, 296, 185-197.	4.0	13
26	Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrates. <i>Toxicology Letters</i> , 2019, 307, 49-58.	0.8	12
27	MicroRNA-mediated Th2 bias in methimazole-induced acute liver injury in mice. <i>Toxicology and Applied Pharmacology</i> , 2016, 307, 1-9.	2.8	11
28	Pathogenetic analyses of carbamazepine-induced liver injury in F344 rats focused on immune- and inflammation-related factors. <i>Experimental and Toxicologic Pathology</i> , 2016, 68, 27-38.	2.1	11
29	Allopurinol induces innate immune responses through mitogen-activated protein kinase signaling pathways in HL-60 cells. <i>Journal of Applied Toxicology</i> , 2016, 36, 1120-1128.	2.8	9
30	Evaluation of Expression and Glycosylation Status of UGT1A10 in Supersomes and Intestinal Epithelial Cells with a Novel Specific UGT1A10 Monoclonal Antibody. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1027-1034.	3.3	9
31	Macrophage-derived extracellular vesicles regulate concanavalin A-induced hepatitis by suppressing macrophage cytokine production. <i>Toxicology</i> , 2020, 443, 152544.	4.2	9
32	Interpretation of the Effects of Protein Kinase C Inhibitors on Human UDP-glucuronosyltransferase 1A (UGT1A) Proteins in cellulo. <i>Drug Metabolism and Pharmacokinetics</i> , 2011, 26, 256-265.	2.2	8
33	Establishment of a novel mouse model for pioglitazone-induced skeletal muscle injury. <i>Toxicology</i> , 2017, 382, 1-9.	4.2	8
34	Establishment of a mouse model of enalapril-induced liver injury and investigation of the pathogenesis. <i>Laboratory Investigation</i> , 2017, 97, 833-842.	3.7	8
35	Fluoroquinolones and propionic acid derivatives induce inflammatory responses in vitro. <i>Cell Biology and Toxicology</i> , 2018, 34, 65-77.	5.3	8
36	Establishment of a mouse model of troglitazone-induced liver injury and analysis of its hepatotoxic mechanism. <i>Journal of Applied Toxicology</i> , 2019, 39, 1541-1556.	2.8	8

#	ARTICLE	IF	CITATIONS
37	Recent progress in the use of microRNAs as biomarkers for drug-induced toxicities in contrast to traditional biomarkers: A comparative review. Drug Metabolism and Pharmacokinetics, 2021, 37, 100372.	2.2	8
38	Exploration of small RNA biomarkers for testicular injury in the serum exosomes of rats. Toxicology, 2020, 440, 152490.	4.2	7
39	Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. Drug Metabolism and Pharmacokinetics, 2016, 31, 210-217.	2.2	6
40	Acute kidney injury model established by systemic glutathione depletion in mice. Journal of Applied Toxicology, 2019, 39, 919-930.	2.8	5
41	Strain and interindividual differences in lamotrigine-induced liver injury in mice. Journal of Applied Toxicology, 2019, 39, 451-460.	2.8	4
42	Neutrophil depletion protects against zomepirac-induced acute kidney injury in mice. Chemico-Biological Interactions, 2018, 279, 102-110.	4.0	2
43	Plasma miR-218 as a biomarker for acute cholestatic liver injury in rats and investigation of its pathophysiological roles. Journal of Applied Toxicology, 2021, 41, 1537-1552.	2.8	2
44	Characterization of human UGT2A3 expression using a prepared specific antibody against UGT2A3. Drug Metabolism and Pharmacokinetics, 2019, 34, 280-286.	2.2	1
45	Pharmacological evidence for the involvement of ryanodine receptors in halothane-induced liver injury in mice. Toxicology, 2020, 443, 152560.	4.2	1
46	Recent Progress and Prospect of Drug Metabolism/Pharmacokinetics Research Contributing to Drug Development. Kagaku To Seibutsu, 2017, 55, 412-420.	0.0	0